Healthcare AI: Build vs. Buy vs. Orchestrate — A 2026 Decision Framework

#What 'Healthcare AI Build vs. Buy' Actually Means in 2026

The build vs. buy question used to be a simple binary: hire engineers or sign a vendor contract. In healthcare AI, that framing broke down once large language models became accessible through APIs and every EHR vendor started bundling AI add-ons. Today the real decision spans a spectrum of five distinct paths, each with different implications for cost, clinical safety, data governance, and who ultimately controls the intelligence layer running inside a health system.

The stakes are higher than in most industries because healthcare AI decisions sit inside a regulated perimeter. ONC's HTI-1 rule now requires certified health IT to disclose how predictive decision support tools were developed and validated, and the FDA has cleared well over a thousand AI/ML-enabled medical devices. A CIO or CMIO choosing a path in 2026 isn't just picking a tool; they're picking a long-term posture toward data ownership, auditability, and vendor dependence that will be difficult to unwind later.

Complicating matters further, most health systems don't make this decision once. A radiology department might buy a point solution for imaging triage while a revenue-cycle team calls a foundation model API directly and a digital-health innovation group experiments with an in-house build, all inside the same organization. Without a shared framework, these choices accumulate into a patchwork of contracts, data pipelines, and governance gaps that no single team owns, which is exactly the condition this framework is meant to help leaders avoid.

#Comparing the 5 Paths Healthcare Orgs Take to Get AI Live

Most healthcare organizations end up somewhere on this spectrum, often without having deliberately chosen it.

• Build in-house: A dedicated data science and ML engineering team designs, trains, and maintains models internally. This offers maximum control and IP ownership but demands rare clinical-ML talent, long timelines, and ongoing MLOps investment most provider organizations struggle to sustain.
• Buy a point solution: A packaged, single-purpose product (ambient documentation, prior-auth automation, imaging triage) is licensed from a specialty vendor. Fast to deploy and narrowly excellent at one job, but each workflow needs its own contract, integration, and vendor relationship, multiplying overhead as use cases grow.
• Hire a fractional AI officer or consultancy: An outside advisor or interim executive is brought in to set strategy, vet vendors, and stand up governance. Useful for organizations without internal AI leadership, but the resulting roadmap and institutional knowledge often walk out the door when the engagement ends.
• Use a foundation model API directly: Engineers wire application logic straight to a provider's API (OpenAI, Anthropic, Google). This is flexible and fast to prototype, but every production query is billed and processed by the vendor indefinitely, and the organization never accumulates a proprietary, exportable asset.
• Use an orchestration platform: A layer sits above foundation models and workflows, capturing real production usage and clinician feedback, then converting that signal into a smaller, owned custom model over time. This path aims to combine buy-level speed with build-level ownership.

#The Critical Gap: Renting Intelligence Means Owning Nothing

Three of the five paths above, buying a point solution, using a consultancy, and calling a foundation model API directly, share a hidden commonality: they are all forms of renting intelligence. The organization pays per use, per seat, or per token, indefinitely, and every dollar spent makes the vendor's model smarter while the health system's own institutional knowledge stays locked inside someone else's weights. This is the 'tenant economy' of enterprise AI: perpetual occupancy, zero equity.

The alternative is an 'asset economy,' where production usage, the millions of real clinical and operational interactions an organization already generates, gets treated as raw material for building something the organization owns outright. A tenant renews a lease forever; an asset owner eventually holds a deed. For healthcare specifically, this distinction compounds over time: every clinical workflow, every subject-matter-expert correction, every documented edge case is proprietary domain knowledge that, under a rental model, evaporates back into a vendor's general-purpose system instead of accumulating as institutional value the health system can point to, govern, and eventually take with them.

This is not an abstract concern. A health system that has spent three years and millions of dollars on API calls to a third-party foundation model has, at the end of that period, nothing more than it started with beyond some application code: no proprietary model weights, no exportable asset, and no leverage in the next contract renewal. Contrast that with an organization that spent the same three years accumulating labeled, validated production data, which can be distilled into a smaller, owned model at any point. The tenant economy optimizes for the vendor's balance sheet; the asset economy optimizes for the health system's own long-term equity in its AI capability.

#An Honest Assessment of the Build and Buy Extremes

On the point-solution end, vendors like Abridge and Nabla have built genuinely strong ambient clinical documentation products: purpose-built for the exam room, fast to roll out, and well-regarded in market research such as KLAS's ambient AI coverage. Their limitation isn't quality, it's scope. A health system adopting five or six of these narrow tools ends up managing five or six separate contracts, data flows, and update cycles, with no shared learning between them and no path to a unified, owned model of the organization's own clinical language and workflows.

On the foundation-model end, calling OpenAI's API, Azure OpenAI Service, or Google's Vertex AI directly gives engineering teams enormous flexibility and the fastest possible prototype-to-pilot timeline. But it is architecturally a rental: the organization has no mechanism to convert months of production traffic into a smaller, cheaper, more accurate model it owns, and every architecture decision remains dependent on a third party's roadmap, pricing, and API stability. Both extremes are reasonable starting points; neither, on its own, produces a durable asset.

It's also worth being honest about where each extreme tends to fail in practice. Point solutions frequently stall at departmental adoption because the value they capture doesn't transfer to the next use case a health system wants to tackle. Direct API integrations frequently stall at the pilot-to-production transition because nobody has planned for the compounding token costs, latency, or compliance documentation that come with running a general-purpose model at hospital scale. Neither failure mode is a reason to avoid these tools entirely; it's a reason to treat them as a starting point rather than a destination.

#The Empromptu Approach: Orchestration, Not Rental

Empromptu's orchestration layer is built on a premise that healthcare organizations don't need to choose between the speed of buying and the ownership of building: production usage itself can become the training ground for a proprietary model. Instead of routing every clinical or operational query to a rented foundation model forever, Empromptu sits above the workflow, capturing real interactions as they happen and treating them as the raw material for something the organization will eventually own.

That process, which Empromptu calls Alchemy, runs in three stages: production usage is logged and analyzed as clinicians and staff actually work; subject-matter experts label and correct the highest-value interactions, encoding institutional judgment that generic models don't have; and a custom model is distilled and exported from that labeled signal, becoming an asset the health system controls rather than a subscription it keeps paying for. Governance, auditability, and compliance controls run underneath the whole pipeline, so the organization never sacrifices the oversight that HTI-1 and FDA expectations increasingly demand.

The result is a health system that starts in the tenant economy, using foundation models and point solutions to get value on day one, and exits into the asset economy, holding a smaller, cheaper, more accurate model built from its own real usage. That model can be audited, retrained, and, critically, exported, so the organization is never permanently dependent on any single vendor's pricing or roadmap.